RESUMEN
OBJECTIVES: QVA149 is a dual bronchodilator, containing a fixed-dose combination of the long-acting ß2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium, for the treatment of chronic obstructive pulmonary disease (COPD). Here we assess the potential of QVA149 (440/200 µg) at 4-fold the therapeutic dose for causing cardiac pharmacodynamic (PD) effects. METHODS: This double-blind, randomized study estimated the time-matched largest heart rate (HR) change and average HR change (over 24 hours) from baseline for QVA149 vs. placebo in healthy subjects. Similar analyses were done for QVA149 vs. indacaterol 600 µg, glycopyrronium 200 µg, and salmeterol 200 µg. The time-matched and average change from baseline in QT interval corrected for HR using Fridericia's formula (QTcF), effects on serum potassium and blood glucose, pharmacokinetic (PK) parameters, and safety were also assessed. RESULTS: Of 50 subjects randomized, 43 completed the study. QVA149, when compared with placebo, showed the time-matched largest mean increase and decrease in HR of 5.69 bpm and -2.51 bpm, respectively, and average HR change from baseline of 0.62 bpm. QVA149 showed no tachycardic potential compared with indacaterol and no relevant tachycardic effect compared with glycopyrronium. No consistent differences were seen in the time-matched largest mean change and average change from baseline in QTcF for QVA149 vs. other treatments. There were no relevant effects of QVA149 on serum potassium and blood glucose. There was no apparent PK/PD relationship between the observed exposures to indacaterol and glycopyrronium in QVA149 on HR and QTcF. There were no deaths or serious adverse events. CONCLUSION: Overall, short-term administration of QVA149 showed a good cardiovascular safety and tolerability profile in healthy subjects.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2/efectos adversos , Bronquios/efectos de los fármacos , Broncodilatadores/efectos adversos , Glicopirrolato/análogos & derivados , Frecuencia Cardíaca/efectos de los fármacos , Indanos/efectos adversos , Antagonistas Muscarínicos/efectos adversos , Quinolonas/efectos adversos , Adolescente , Agonistas de Receptores Adrenérgicos beta 2/farmacocinética , Adulto , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Broncodilatadores/farmacocinética , Estudios Cruzados , Método Doble Ciego , Combinación de Medicamentos , Femenino , Glicopirrolato/efectos adversos , Glicopirrolato/farmacocinética , Voluntarios Sanos , Humanos , Indanos/farmacocinética , Masculino , Persona de Mediana Edad , Antagonistas Muscarínicos/farmacocinética , Seguridad del Paciente , Potasio/sangre , Quinolonas/farmacocinética , Medición de Riesgo , Factores de Riesgo , Adulto JovenRESUMEN
This dose-ranging study assessed the bronchodilator efficacy and tolerability of indacaterol, a novel once-daily inhaled beta2-agonist, in subjects clinically diagnosed with COPD. Comparative data with tiotropium were collected. In the double-blind, core period of the study, 635 subjects with COPD (prebronchodilator FEV(1)40% of predicted and > or =1.0L; FEV1/FVC <70%) were randomized to receive indacaterol 50, 100, 200 or 400microg or placebo via multi-dose dry powder inhaler, or indacaterol 400microg via single-dose dry powder inhaler, once daily for 7 days. After completing double-blind treatment and washout, a subset of subjects from each treatment group entered an open-label extension and received tiotropium 18microg once daily for 8 days. The primary efficacy variable was the trough bronchodilator effect: standardized area under the FEV1 curve between 22 and 24h post-dose (FEV1 AUC(22-24h)) on Day 1. Clinically relevant improvements versus placebo in FEV1 AUC(22-24h) were seen for 400 and 200microg doses on Day 1 and all doses on Day 7. All indacaterol doses significantly (P<0.05) increased FEV1 from 5min to 24h post-dose; the 400 and 200microg doses were most effective. All doses were well tolerated. Indacaterol trough FEV1 levels compared favorably with the improvement seen by Day 8 in subjects treated with tiotropium in the open-label extension. The results confirm that indacaterol has a 24-h duration of bronchodilator effect and a fast onset of action in COPD and suggest that indacaterol could be an effective once-daily inhaled beta2-agonist bronchodilator. Indacaterol demonstrated a good overall safety and tolerability profile.
Asunto(s)
Broncodilatadores/administración & dosificación , Indanos/administración & dosificación , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Quinolonas/administración & dosificación , Derivados de Escopolamina/administración & dosificación , Administración por Inhalación , Adulto , Anciano , Broncodilatadores/farmacocinética , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Volumen Espiratorio Forzado/fisiología , Humanos , Indanos/farmacocinética , Masculino , Persona de Mediana Edad , Quinolonas/farmacocinética , Derivados de Escopolamina/farmacocinética , Bromuro de Tiotropio , Resultado del TratamientoRESUMEN
Transgenic mice, although useful for analyses of gene function, can present unanticipated phenotypic manifestations, including behavioral problems, that may not be directly associated with the gene of interest but rather due to the complex interplay inherent in genomes. These unexpected events can present unique insight into gene function, leading to an advantage in some situations, yet in others can confound interpretation and compromise usefulness of the transgenic line. Here we document that short-term supplementation with S-adenosyl methionine (SAM)--a nutriceutical known to regulate neurotransmitter levels, improve working memory, and reduce aggression--reduced handling- and startling-induced seizures that otherwise precluded behavioral analyses in a transgenic line. This effect lasted for at least 1 mo after withdrawal of SAM and allowed mice to be used in standard maze analyses. These findings suggest that short-term administration of a neurotropic nutriceutical may provide a functional rescue for behavioral studies in an otherwise intractable transgenic mouse line as well as improve the welfare of similar lines.
Asunto(s)
Suplementos Dietéticos , S-Adenosilmetionina/administración & dosificación , Convulsiones/prevención & control , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/fisiopatología , Enfermedad de Alzheimer/psicología , Animales , Apolipoproteína E4/genética , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Humanos , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Proteínas Recombinantes/genéticaRESUMEN
BACKGROUND: Establishing robust in vitro-in vivo correlations (IVIVC) between aerosol performance, pharmacokinetics, and clinical efficacy is critical in developing bioequivalent drug-device combination products. Recent studies have demonstrated that realistic throat models tested under realistic test conditions may provide good IVIVC with respect to total lung deposition. METHODS: The Alberta idealized throat (AIT) model was utilized with mean peak inspiratory flow rates determined from patient breathing studies. Various formulations of indacaterol (e.g., lactose blends, fixed dose combinations, engineered PulmoSphere™ particles) were tested in the AIT model and in clinical pharmacokinetic studies. RESULTS: Good IVIVC were observed with respect to total lung deposition, systemic delivery, and the contribution of oral absorption to systemic delivery, with percentage differences from the mean in vivo measurements <15%, with most comparisons <5%. CONCLUSIONS: Anatomical throat models represent an exciting tool to aid in formulation development of pharmaceutical aerosols.